32.3 Ambulatory Hypotension & Orthostasis Evaluation

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

32.3 Ambulatory Hypotension & Orthostasis Evaluation

Key Takeaways Explain This Topic AI

Orthostatic hypotension (OH) is clinically defined by a sustained drop in systolic blood pressure of ≥20 mmHg, or a drop in diastolic blood pressure of ≥10 mmHg, within 3 minutes of active standing or 60-degree head-up tilt from a supine baseline (or a ≥30 mmHg systolic drop in patients with baseline supine hypertension ≥160 mmHg).

Heart rate response upon standing differentiates neurogenic OH from non-neurogenic etiologies: an increase of <15 bpm (or a Delta HR / Delta SBP ratio <0.5 bpm/mmHg) indicates neurogenic OH due to autonomic failure (e.g., Parkinson disease, multiple system atrophy, pure autonomic failure, or diabetic autonomic neuropathy), whereas an increase of ≥15 bpm reflects an intact baroreflex compensating for hypovolemia, deconditioning, or vasodilating medications.

Postural Orthostatic Tachycardia Syndrome (POTS) is defined by a sustained heart rate elevation of ≥30 bpm (or ≥40 bpm in adolescents aged 12 to 19 years) within 10 minutes of standing in the ABSENCE of orthostatic hypotension, accompanied by chronic orthostatic symptoms lasting at least 3 months.

Medication reconciliation is the cornerstone of orthostasis evaluation; key culprit classes include alpha-1 blockers, diuretics, vasodilators, nitrates, tricyclic antidepressants, beta-blockers, and SGLT2 inhibitors, which should be discontinued, reduced, or shifted to bedtime dosing whenever feasible.

Non-pharmacologic management is first-line for all orthostasis: 2 to 2.5 L/day fluid intake, 6 to 10 g/day dietary sodium liberalization, waist-high compression garments or abdominal binders (superior to knee-high stockings), physical counter-pressure maneuvers, and 10- to 15-degree head-of-bed elevation; refractory neurogenic OH is managed pharmacologically with daytime midodrine, fludrocortisone, or droxidopa, with careful vigilance to prevent nocturnal supine hypertension.

Last updated: September 2026

Pathophysiology & Consensus Definitions of Orthostatic Hypotension

Upon assuming an upright posture, gravitational forces immediately pool approximately 500 to 1,000 mL of blood into the distensible venous capacitance vessels of the lower limbs, buttocks, and splanchnic circulation. This sudden sequestration diminishes venous return (cardiac preload), triggering a transient decline in stroke volume and cardiac output.

The Normal Baroreflex Compensatory Arc

In healthy individuals, this transient drop in arterial pressure is instantly detected by high-pressure stretch baroreceptors located in the carotid sinus (innervated by the glossopharyngeal nerve, CN IX) and aortic arch (innervated by the vagus nerve, CN X). Afferent signals project to the nucleus tractus solitarius in the medulla oblongata, eliciting two coordinated autonomic responses:

Vagal (Parasympathetic) Withdrawal : Immediate disinhibition of the sinoatrial (SA) node, accelerating the heart rate by 10 to 20 beats per minute within seconds.

Sympathetic Adrenergic Activation : Efferent sympathetic postganglionic fibers discharge norepinephrine, stimulating cardiac beta-1 adrenergic receptors (enhancing chronotropy and inotropy) and vascular alpha-1 adrenergic receptors on systemic arterioles and splanchnic capacitance veins. Arteriolar vasoconstriction increases systemic vascular resistance (SVR), while venoconstriction mobilizes pooled blood back to the right atrium, restoring cardiac output and stabilizing blood pressure within 30 to 60 seconds. NORMAL ORTHOSTATIC BAROREFLEX ARC

• Active Standing / Upright Posture
• │
• ▼
• Gravitational Venous Pooling (500-1000 mL)
• [Lower Extremities & Splanchnic Bed]
• │
• ▼
• Decreased Preload & Cardiac Output
• │
• ▼
• Carotid Sinus & Aortic Baroreceptor Deactivation
• │ (Afferents: CN IX & X)
• ▼
• Medullary Vasomotor Center (NTS)
• │
• ┌──────────────┴──────────────┐
• ▼ ▼
• Parasympathetic Withdrawal Sympathetic Surge (NE)
• Rapid HR increase • Alpha-1: Arteriolar & Splanchnic
• (+10-20 bpm) Vasoconstriction (↑ SVR)
• Beta-1: ↑ Inotropy & Heart Rate
• │
• ▼
• Restoration of Systemic BP
• Consensus Diagnostic Definitions

According to the American Academy of Neurology (AAN), European Society of Cardiology (ESC), and American Autonomic Society (AAS), orthostatic hemodynamic disorders are categorized as follows:

Classical Orthostatic Hypotension (OH) :

A sustained reduction in systolic blood pressure (SBP) of ≥20 mmHg AND/OR a sustained reduction in diastolic blood pressure (DBP) of ≥10 mmHg occurring within 3 minutes of active standing or 60-degree head-up tilt from a resting supine position.

Supine Hypertension Exception : In patients with baseline supine hypertension (supine SBP ≥160 mmHg), a larger systolic drop of ≥30 mmHg is required because absolute pressure declines are amplified at elevated vascular pressures.

Initial Orthostatic Hypotension (IOH) :

A transient, profound blood pressure reduction (SBP drop >40 mmHg or DBP drop >20 mmHg) that occurs immediately upon standing (within 15 seconds), followed by rapid, spontaneous recovery to normal within 30 to 60 seconds.

Mechanism : Mismatch between cardiac output acceleration and transient muscular vasodilation, frequently seen in healthy adolescents, young asthenic adults, or older patients with arterial stiffness.

Delayed (Progressive) Orthostatic Hypotension :

A sustained reduction in SBP ≥20 mmHg or DBP ≥10 mmHg that occurs beyond 3 minutes of upright standing (typically developing between 3 and 30 minutes).

Significance : Represents an early or milder stage of autonomic sympathetic adrenergic failure, often progressing to classical OH over several years.

Postprandial Hypotension :

A decline in SBP of ≥20 mmHg within 2 hours of consuming a meal (predominantly carbohydrate-rich meals) due to excessive splanchnic blood pooling.

Standardized Ambulatory Orthostatic Vital Sign Protocol

Accurate diagnosis requires strict adherence to standardized measurement technique. An informal sitting-to-standing blood pressure check misses up to 35% to 40% of clinically significant orthostatic hypotension because blood has already pooled in the lower extremities while seated.

Step-by-Step Clinical Procedure

Resting Baseline Phase : The patient rests quietly in the supine position for a minimum of 5 minutes in a calm room with normal ambient temperature. Baseline supine blood pressure and heart rate are recorded.

Active Standing Phase : The patient actively stands upright without assistance (or with minimal support). The arm must be supported at heart level during each measurement.

Timed Serial Measurements : Blood pressure and heart rate are measured precisely at 1 minute and 3 minutes after standing. If delayed OH is suspected and 3-minute vitals are normal, continue standing measurements up to 5 to 10 minutes.

Symptom Documentation : The clinician must explicitly document whether the blood pressure drop is accompanied by cerebral hypoperfusion symptoms: lightheadedness, dizziness, blurred or 'graying' vision, tunnel vision, cognitive slowing ("brain fog"), generalized weakness, or "coat-hanger" pain (suboccipital, posterior cervical, and shoulder girdle pain triggered by muscular ischemia of the trapezius and neck extensors during hypotension).

Neurogenic vs. Non-Neurogenic Orthostatic Hypotension

Once orthostatic hypotension is confirmed, the critical clinical task is differentiating neurogenic OH (nOH) from non-neurogenic OH . This distinction governs prognostic implications and dictates whether treatment focuses on volume/medication correction versus specialized neuro-pharmacotherapy.

The Heart Rate Delta (ΔHR) Metric

The compensatory heart rate response during standing serves as a reliable surrogate for autonomic baroreflex integrity:

Neurogenic Orthostatic Hypotension (nOH) : Characterized by a blunted compensatory heart rate response :

Heart rate increases by <15 beats per minute (bpm) upon standing, despite a significant drop in blood pressure.

The Delta HR / Delta SBP Ratio : ΔHR / ΔSBP < 0.5 bpm/mmHg.

Mechanism : Pathologic destruction of postganglionic sympathetic adrenergic neurons or central medullary vasomotor centers abolishes the efferent reflex arc.

Non-Neurogenic Orthostatic Hypotension : Characterized by an intact compensatory reflex tachycardia :

Heart rate increases appropriately by ≥15 beats per minute upon standing (often exceeding 20 to 30 bpm).

The baroreflex arc is structurally intact and actively fighting hypovolemia or drug-induced vasodilation.

Diagnostic Parameter Neurogenic Orthostatic Hypotension (nOH) Non-Neurogenic Orthostatic Hypotension

Heart Rate Response (ΔHR) Blunted (<15 bpm increase) ; failure of reflex chronotropy Intact (≥15 bpm increase) ; robust compensatory tachycardia

ΔHR / ΔSBP Ratio <0.5 bpm/mmHg >0.5 bpm/mmHg

Primary Pathophysiology Efferent autonomic failure; impaired vascular norepinephrine release Intact baroreflex responding to hypovolemia, vasodilation, or pump failure

Primary Central Etiologies Alpha-Synucleinopathies :; • Parkinson Disease (PD); • Multiple System Atrophy (MSA / Shy-Drager); • Dementia with Lewy Bodies (DLB); • Pure Autonomic Failure (PAF) Not applicable (baroreflex intact)

Primary Peripheral Etiologies Autonomic Neuropathies :; • Diabetic Autonomic Neuropathy (DAN); • AL / ATTR Amyloidosis; • Autoimmune Autonomic Ganglionopathy; • Paraneoplastic (anti-Hu), Sjogren, B12 deficiency Volume Depletion / Endocrine :; • Dehydration, hemorrhage, vomiting, diarrhea; • Primary Adrenal Insufficiency (Addison disease); • Sepsis, severe varicose veins with venous pooling

Medication Role Exacerbates underlying baseline denervation Frequently the primary or sole cause of hypotension

Nocturnal Supine Blood Pressure Frequent severe supine hypertension (loss of day/night dip) Usually normal or low supine blood pressure

Postural Orthostatic Tachycardia Syndrome (POTS)

Postural Orthostatic Tachycardia Syndrome (POTS) is a distinct disorder of orthostatic intolerance that must never be confused with orthostatic hypotension.

Consensus Diagnostic Criteria for POTS

Sustained Heart Rate Increase : An increase in heart rate of ≥30 bpm (or an absolute standing heart rate of ≥120 bpm ) occurring within 10 minutes of standing (or head-up tilt test).

Pediatric / Adolescent Exception : In individuals aged 12 to 19 years , a threshold increase of ≥40 bpm is required due to higher baseline physiologic heart rate variability in youth.

ABSENCE of Orthostatic Hypotension : Systolic blood pressure does NOT drop ≥20 mmHg , and diastolic blood pressure does NOT drop ≥10 mmHg . Blood pressure remains stable or may paradoxically rise slightly.

Chronicity : Symptoms of orthostatic intolerance (palpitations, tremulousness, lightheadedness, chest tightness, exercise intolerance, cognitive dysfunction) must be present for at least 3 to 6 months .

Exclusion of Secondary Causes : Exclusion of overt dehydration, acute blood loss, hyperthyroidism, pheochromocytoma, prolonged bed rest deconditioning, or culprit tachycardic medications.

Clinical Phenotypes & Epidemiology

Demographics : Strongly female-predominant (~80% to 85% female), typically presenting between 15 and 45 years of age. Often triggered post-virally (e.g., following EBV or COVID-19 infection).

Management Overview : High dietary fluid (2.5 to 3.0 L/day) and sodium (8 to 10 g salt/day); waist-high compression garments; structured exercise reconditioning using recumbent aerobic modalities (Levine / Dallas protocol: rowing machine, recumbent bicycle, swimming) before upright exercise; off-label pharmacotherapy includes low-dose propranolol (10 to 20 mg), fludrocortisone, midodrine, pyridostigmine, or ivabradine.

Culprit Medications & Rational Deprescribing Strategies

Medication-induced vasodilation or volume depletion represents the single most common cause of orthostatic hypotension in older adults. Systematic review and stepwise deprescribing is the mandatory first therapeutic intervention:

Culprit Medication Class Specific Offending Agents Pathophysiologic Mechanism Deprescribing / Modification Strategy

Alpha-1 Adrenergic Receptor Blockers Terazosin, doxazosin, prazosin; tamsulosin, alfuzosin Direct blockade of vascular alpha-1 receptors on arterioles and venules, paralyzing compensatory vasoconstriction High-risk culprit. Discontinue terazosin/doxazosin. For BPH, switch to 5-alpha-reductase inhibitors (finasteride) or uroselective tamsulosin taken at bedtime.

Diuretics Furosemide, bumetanide, hydrochlorothiazide, chlorthalidone Contraction of effective circulating plasma volume; prerenal azotemia Taper or discontinue diuretics if signs of hypovolemia exist; reduce dose when target weight is reached in heart failure.

Beta-Adrenergic Blockers Metoprolol, atenolol, propranolol, carvedilol Blunts compensatory reflex tachycardia (suppresses chronotropic reserve); carvedilol adds alpha-1 blockade Taper or switch to an ACE inhibitor or dihydropyridine CCB if prescribed solely for uncomplicated hypertension.

Direct Vasodilators & Nitrates Hydralazine, minoxidil, isosorbide mononitrate, nitroglycerin Arteriolar and venous relaxation, profound venous capacitance pooling Avoid long-acting nitrates in elderly frail outpatients; discontinue hydralazine if alternative antihypertensives exist.

Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil, tadalafil, vardenafil cGMP-mediated vascular smooth muscle relaxation STRICT CONTRAINDICATION : Co-administration with nitrates causes catastrophic, refractory, life-threatening hypotension.

Tricyclic Antidepressants (TCAs) Amitriptyline, nortriptyline, imipramine Potent alpha-1 adrenergic receptor antagonism (in addition to anticholinergic effects) Extremely high fall risk in elderly. Discontinue TCAs; switch to SSRIs (e.g., sertraline) or SNRIs.

SGLT2 Inhibitors Empagliflozin, dapagliflozin Osmotic diuresis and mild volume contraction (~1.5 L plasma volume loss) Monitor volume status closely upon initiation, especially when combined with loop diuretics.

Centrally Acting Alpha-2 Agonists Clonidine, guanfacine Suppresses central sympathetic vasomotor outflow from the brainstem Avoid in elderly; if discontinuing, taper very slowly over weeks to prevent severe rebound hypertensive crisis.

Stepwise Non-Pharmacologic Management of Orthostasis

Non-pharmacologic interventions form the foundational cornerstone of management for all patients with orthostatic intolerance and should always be maximized prior to initiating vasoactive pharmacotherapy: STEPWISE NON-PHARMACOLOGIC THERAPY FOR OH

• 1. FLUID & SALT EXPANSION ──> 2.0 to 2.5 L water/day + 6 to 10 g NaCl/day
• Acute cold-water bolus (500 mL) before rising
• 2. EXTERNAL COMPRESSION ──> Abdominal binder (most effective) +
• Waist-high compression stockings (30-40 mmHg)
• 3. PHYSICAL MANEUVERS ──> Leg crossing, squatting, buttock clenching
• 4. SLEEP MODIFICATION ──> Elevate head of bed by 10 to 15 degrees
• (Reduces nocturnal natriuresis & supine HTN)
• 5. POSTURAL HYGIENE ──> Phased rising, avoid hot showers & carb binges

Intravascular Volume Expansion :

Daily Fluid Intake : Consume 2.0 to 2.5 liters of water daily .

Acute Water Bolus Trick : Rapidly drinking 500 mL of cold tap water within 3 to 5 minutes produces a robust pressor effect mediated by an osmoreceptive sympathetic spinal reflex. It raises systolic blood pressure by 20 to 35 mmHg within 15 to 30 minutes, lasting up to 90 minutes. Patients should execute this maneuver immediately before getting out of bed in the morning or before meals.

Dietary Sodium Liberalization : In the absence of severe congestive heart failure or advanced chronic kidney disease, increase daily salt intake to 6 to 10 grams of sodium chloride (equivalent to 1 to 2 level teaspoons of added table salt or commercial sodium chloride tablets 1 g TID with meals).

Targeted External Compression Garments :

Abdominal Binders : Clinical Pearl : The splanchnic mesenteric venous bed pools more than 25% to 30% of the total circulating blood volume. Therefore, an elastic abdominal binder (tightly fastened before rising) is significantly more effective at preventing orthostatic drops than lower-leg stockings .

Waist-High Graduated Compression Stockings : 30 to 40 mmHg compression. Pitfall : Knee-high compression socks are largely ineffective for orthostatic hypotension because they fail to compress the thigh and splanchnic venous reservoirs.

Physical Counter-Pressure Maneuvers :

Teach the patient to perform isometric skeletal muscle contraction maneuvers at the first onset of presyncopal symptoms:

Leg Crossing : Crossing legs while standing and tensing calf, thigh, and gluteal muscles.

Squatting : Deep squatting compresses femoral and popliteal veins, instantly restoring venous return.

Toe-Raising & Calf Pumping : Actively contracting calf muscle pumps prior to stepping out of bed.

Sleep & Postural Hygiene :

Head-of-Bed Elevation : Elevate the head of the bed by 10 to 15 degrees (approximately 6 to 9 inches) using bed risers or an under-mattress wedge (stacking pillows is ineffective because it flexes the neck without raising the torso). Mechanism : Head-up sleeping prevents the renal arterial pressure elevation that drives nocturnal pressure natriuresis, preserving blood volume overnight and preventing early morning dehydration.

Phased Posture Shifts : Sit on the edge of the bed with feet dangling for 1 to 2 minutes before standing.

Meal Adjustments : Eat smaller, frequent, low-carbohydrate meals to mitigate postprandial splanchnic pooling; avoid alcohol and very hot showers/baths.

Targeted Pharmacotherapy for Refractory Neurogenic Orthostatic Hypotension

Pharmacologic therapy is reserved strictly for patients with confirmed neurogenic orthostatic hypotension whose symptoms and functional limitations persist despite comprehensive non-pharmacologic optimization:

1. Midodrine Hydrochloride (Selective Alpha-1 Adrenergic Agonist)

Mechanism : An oral prodrug rapidly hydrolyzed to desglymidodrine , a selective direct alpha-1 adrenergic agonist. Induces direct arteriolar and venous vasoconstriction without stimulating cardiac beta-receptors.

Dosing Regimen : Initiate at 2.5 to 5 mg PO three times daily ; titrate by 2.5 to 5 mg increments up to a maximum of 10 mg PO three times daily .

Timing of Administration : Doses should be spaced 4 hours apart during active daytime hours (e.g., 8:00 AM, 12:00 PM, and 4:00 PM).

CRITICAL BLACK BOX WARNING: Nocturnal Supine Hypertension :

Midodrine can provoke severe, dangerous supine hypertension (SBP >180-200 mmHg), risking hemorrhagic stroke and myocardial infarction.

Mandatory Patient Instructions : Doses must only be taken when the patient will be upright and active. The final daily dose MUST be taken at least 4 hours before bedtime (never after 6:00 PM) , and the patient must never lie flat while the drug is active.

Adverse Effects : Scalp paresthesias and tingling, piloerection ("goosebumps"), urinary retention (bladder neck constriction), and reflex bradycardia.

2. Fludrocortisone Acetate (Synthetic Mineralocorticoid)

Mechanism : Potent mineralocorticoid analog that stimulates renal distal convoluted tubule and collecting duct sodium reabsorption, expanding extracellular and intravascular fluid volume. Long-term use also enhances vascular smooth muscle alpha-adrenergic sensitivity.

Dosing Regimen : Initiate at 0.1 mg PO once daily in the morning ; may titrate after 1 to 2 weeks to 0.2 mg daily (doses >0.2 mg offer minimal additional benefit and markedly increase toxicity).

Crucial Requirement : Fludrocortisone requires adequate dietary sodium intake to be effective; patients must continue liberal salt intake.

Monitoring & Adverse Effects : Severe hypokalemia (monitor serum potassium closely and provide oral potassium repletion as needed), supine hypertension, peripheral lower extremity edema, and exacerbation of congestive heart failure.

3. Droxidopa (L-threo-dihydroxyphenylserine / L-DOPS)

Mechanism : A synthetic amino acid prodrug converted directly into active norepinephrine by endogenous dopa-decarboxylase (L-aromatic-amino-acid decarboxylase), replenishing depleted synaptic norepinephrine stores in peripheral sympathetic nerve endings.

Indications : FDA-approved specifically for neurogenic OH associated with primary autonomic disorders: Parkinson disease, Multiple System Atrophy (MSA), and Pure Autonomic Failure (PAF).

Dosing Regimen : Start at 100 mg PO three times daily upon waking, midday, and late afternoon (take last dose at least 3 to 4 hours before sleep). Titrate in 100-mg increments up to a maximum of 600 mg PO three times daily .

Adverse Effects : Supine hypertension, headache, dizziness, nausea.

4. Pyridostigmine (Acetylcholinesterase Inhibitor)

Mechanism : Inhibits acetylcholinesterase at autonomic ganglionic nicotinic synapses. Because acetylcholine release at sympathetic ganglia is activity-dependent (occurring primarily during upright posture), pyridostigmine increases standing vascular tone without causing significant supine hypertension .

Dosing : 30 to 60 mg PO two to three times daily, frequently combined with low-dose midodrine for synergistic benefit.

Loading diagram... Comprehensive Diagnostic & Management Flowchart for Orthostatic Intolerance